Overview
The marketing authorisation for Clopidogrel 1A Pharma has been withdrawn at the request of the marketing authorisation holder.
Clopidogrel 1A Pharma : EPAR - Summary for the public
English (EN)
(264.06 KB - PDF)View
български (BG)
(429 KB - PDF)
español (ES)
(266.07 KB - PDF)
čeština (CS)
(400.48 KB - PDF)
dansk (DA)
(265.13 KB - PDF)
Deutsch (DE)
(267 KB - PDF)
eesti keel (ET)
(264.62 KB - PDF)
ελληνικά (EL)
(443.13 KB - PDF)
français (FR)
(266.53 KB - PDF)
italiano (IT)
(265.52 KB - PDF)
latviešu valoda (LV)
(399.98 KB - PDF)
lietuvių kalba (LT)
(398.13 KB - PDF)
magyar (HU)
(390.37 KB - PDF)
Malti (MT)
(401.02 KB - PDF)
Nederlands (NL)
(265.96 KB - PDF)
polski (PL)
(407.58 KB - PDF)
português (PT)
(265.9 KB - PDF)
română (RO)
(370.65 KB - PDF)
slovenčina (SK)
(426.4 KB - PDF)
slovenščina (SL)
(354.65 KB - PDF)
Suomi (FI)
(264.89 KB - PDF)
svenska (SV)
(265.24 KB - PDF)
Product information
Clopidogrel 1A Pharma : EPAR - Product Information
English (EN)
(512.52 KB - PDF)View
български (BG)
(1.19 MB - PDF)
español (ES)
(525.85 KB - PDF)
čeština (CS)
(854.23 KB - PDF)
dansk (DA)
(520.45 KB - PDF)
Deutsch (DE)
(531.69 KB - PDF)
eesti keel (ET)
(512.36 KB - PDF)
ελληνικά (EL)
(1.26 MB - PDF)
français (FR)
(537.44 KB - PDF)
italiano (IT)
(522.87 KB - PDF)
latviešu valoda (LV)
(944.42 KB - PDF)
lietuvių kalba (LT)
(588.7 KB - PDF)
magyar (HU)
(893 KB - PDF)
Malti (MT)
(869.35 KB - PDF)
Nederlands (NL)
(538.17 KB - PDF)
polski (PL)
(926.14 KB - PDF)
português (PT)
(457.39 KB - PDF)
română (RO)
(600.83 KB - PDF)
slovenčina (SK)
(870.69 KB - PDF)
slovenščina (SL)
(801.06 KB - PDF)
Suomi (FI)
(524.94 KB - PDF)
svenska (SV)
(535.63 KB - PDF)
Latest procedure affecting product information: IA/0002
01/02/2011
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Clopidogrel 1A Pharma : EPAR - All Authorised presentations
English (EN)
(224.85 KB - PDF)View
български (BG)
(310.7 KB - PDF)
español (ES)
(225.32 KB - PDF)
čeština (CS)
(298.64 KB - PDF)
dansk (DA)
(224.99 KB - PDF)
Deutsch (DE)
(225.22 KB - PDF)
eesti keel (ET)
(225.28 KB - PDF)
ελληνικά (EL)
(321.04 KB - PDF)
français (FR)
(225.74 KB - PDF)
italiano (IT)
(224.99 KB - PDF)
latviešu valoda (LV)
(300.54 KB - PDF)
lietuvių kalba (LT)
(304.46 KB - PDF)
magyar (HU)
(301.3 KB - PDF)
Malti (MT)
(298.46 KB - PDF)
Nederlands (NL)
(225.08 KB - PDF)
polski (PL)
(265.23 KB - PDF)
português (PT)
(225.13 KB - PDF)
română (RO)
(287.24 KB - PDF)
slovenčina (SK)
(263.63 KB - PDF)
slovenščina (SL)
(234.23 KB - PDF)
Suomi (FI)
(225.23 KB - PDF)
svenska (SV)
(225.69 KB - PDF)
Product details
- Name of medicine
- Clopidogrel 1A Pharma
- Active substance
- clopidogrel
- International non-proprietary name (INN) or common name
- clopidogrel
- Therapeutic area (MeSH)
- Peripheral Vascular Diseases
- Anatomical therapeutic chemical (ATC) code
- B01AC04
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
- Patients suffering from acute coronary syndrome:
- - Non ST segment elevation acute coronary syndrome (unstable angina or non Q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
For further information please refer to section 5.1.
Assessment history
Clopidogrel 1A Pharma : EPAR - Public assessment report
English (EN)
(411.1 KB - PDF)View
This page was last updated on